[Transfusion-induced immunomodulation and infectious complications].

Area of Science:

• Immunology
• Transfusion Medicine
• Oncology

Background:

• Blood transfusions, while life-saving, carry inherent risks.
• Transfusion-induced immunomodulation (TRIM) encompasses both immunosuppression and pro-inflammatory effects.
• TRIM is implicated in adverse outcomes such as transfusion-related acute lung injury (TRALI), multiorgan failure (MOF), and transfusion-associated graft-versus-host disease (TAGvHD).

Purpose of the Study:

• To elucidate the mechanisms and consequences of transfusion-induced immunomodulation (TRIM).
• To highlight the association between TRIM and increased risks of nosocomial infections and tumor relapse.
• To emphasize the impact of blood product storage duration and leukoreduction on TRIM potential.

Main Methods:

• Review of existing literature on transfusion immunology and clinical outcomes.
• Analysis of factors contributing to TRIM, including microchimerism, cellular components, and soluble factors like complement components (e.g., C3a), soluble HLA molecules, and soluble Fas ligand (sFasL).
• Evaluation of the influence of storage time and leukoreduction on the immunomodulatory capacity of blood products.

Main Results:

• TRIM can lead to severe complications, including secondary infections (pulmonary, sepsis, wound) and increased tumor recurrence rates in cancer patients.
• The development of TRIM is linked to microchimerism and the presence of soluble factors such as C3a, soluble HLA, and sFasL.
• The immunosuppressive potential of blood products significantly increases with prolonged storage, particularly in non-leukoreduced products.

Conclusions:

• Careful consideration of transfusion risks versus benefits is crucial.
• Minimizing TRIM potential through optimized blood product management (e.g., storage duration, leukoreduction) may improve patient outcomes.
• Further research into mitigating TRIM is warranted to enhance transfusion safety.